Lymphoma Clinical Trials in Ohio

Showing 401-420 of 714 trials

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

NCT01728207

IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.

Non-hodgkin's LymphomaFollicular LymphomaMantle Cell Lymphoma+3 more

Gilead Sciences30 participantsStarted Mar 2013

Newark, Delaware, United States • Savannah, Georgia, United States • Goshen, Indiana, United States +2 more locations

COMPLETEDPhase 232 miles

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

NCT01190449

RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This randomized phase II trial is studying ofatumumab to see how well it works in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.

Lymphoma

Alliance for Clinical Trials in Oncology51 participantsStarted Aug 2011

Lewes, Delaware, United States • Newark, Delaware, United States • Weston, Florida, United States +45 more locations

PreviousPage 21 of 36Next

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Lymphoma Trials in Other Cities

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Other Conditions in Ohio